Abstract Inherited retinopathies are devastating diseases that in most cases lack treatment options. Disease-modifying therapies that mitigate pathophysiology regardless of the underlying genetic lesion are
Abstract Doxorubicin, the most prescribed chemotherapeutic drug, causes dose-dependent cardiotoxicity and heart failure. However, our understanding of the immune response elicited by doxorubicin is limited.
Summary Background Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive dyskinesia. To address the ongoing need for
Abstract The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K–mutated melanoma is limited and transient. Resistance largely
Abstract Background Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children
MIT engineers, in collaboration with scientists from Brigham and Women’s Hospital and Novo Nordisk, are developing a drug capsule technology that could allow the oral
Highlights –IFN expression in COVID-19 varies based on location, viral load, age, and severity –IFN-λ1 and -λ3 drive protective ISGs in the upper airways of
Highlights •Unsupervised clustering revealed subtype with EMT and phosphoprotein signatures •Potential therapeutic vulnerabilities included survivin, NSD3, LSD1, and EZH2 •Rb phosphorylation nominated as a biomarker
A new drug offers hope for young boys with the progressive neuromuscular disease Duchenne muscular dystrophy (DMD) by potentially offering an alternative to high-dose glucocorticoids
The US Food and Drug Administration approved a Duchenne muscular dystrophy drug yesterday (December 13) that it had originally rejected in August, reports STAT. The
Long-acting medicines have proved as effective as daily pills in preventing HIV from replicating, according to results from twin trials that enrolled more than 1,000
As the opioid crisis continues to ravage U.S. communities, scientists and drug companies have intensified their efforts to develop safer and less addictive pain medications.
An investigative report uncovers little recognized and unpoliced potential conflicts of interest among those who serve on FDA advisory panels that review drugs. Some members
What is a best-selling drug worth? In 2013, at least, it came down to at least $3 billion in annual sales—triple the $1 billion benchmark
In 2014, Miriam van Staveren went on holiday to the Canary Islands and caught an infection. Her ear and sinuses throbbed, so she went to
One of the major challenges of the current Zika virus (ZIKV) epidemic is to prevent congenital foetal abnormalities, including microcephaly, following ZIKV infection of pregnant
Summary Nearly all of the roughly 64,000 Americans who died from opioid overdoses in 2016 succumbed because their breathing shut down, triggered by the effects
Even where drugs did show survival gains over existing treatments, these were often marginal, the results show. Many of the drugs were approved on the
Abstract Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2. The mechanism by which these drugs interact with
Therapies that target signalling molecules that are mutated in cancers can often have substantial cartier replica short-term effects, but cartier love bracelet the emergence of
Results of a phase II, multicenter, double-blind, placebo-controlled, multiple-ascending-dose clinical trial confirmed that the experimental small interfering RNA (siRNA) drug inclisiran was effective for treating
While political scenarios facing the world have many people nervous about what kind of future we face, there is a microscopic war that is constantly
Eli Lilly officials report that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a Phase III study of the drug in
The Merck KGaA/Pfizer co-developed immune checkpoint inhibitor Avelumab will be assessed in combination with Vaccinex’s VX15/2503 through a clinical collaboration whose value was not disclosed.
The Merck KGaA/Pfizer co-developed immune checkpoint inhibitor Avelumab will be assessed in combination with Vaccinex’s VX15/2503 through a clinical collaboration whose value was not disclosed.
Created by ePubSystems. Contact Us for similar site for your university or institute.